• The global electric boats market is forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030
• Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time
• The company’s new chief financial officer brings invaluable expertise and insight in manufacturing, production and delivery

As the electric boat sector is projected to double in value in the next few years, companies operating in the industry are positioning themselves to meet — and even exceed — the expectations this growth could create. For example, Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating market, has made two key announcements recently: the company unveiled its Phantom vessel, a new rotomolded, recyclable, and hard-to-damage boat (https://ibn.fm/n0Ytr), and it named an industry veteran as it transitions to the manufacturing and delivery phase (https://ibn.fm/O8OPk).

The global electric boats market is on the cusp of significant growth, with the market forecast to more than double in size, increasing from $3.3 billion in 2023 to $7.7 billion by 2030, reported ResearchandMarket.com (https://ibn.fm/0dMHk). “This remarkable expansion is set to soar at a compound annual growth rate (“CAGR”) of 13.0% from 2023 to 2030,” the report stated. “The driving force behind this surge is the escalating demand for advanced electrical systems in electric boats.

“The electric boats market is poised for transformation, driven by the increasing demand for sustainable transportation solutions, mounting environmental concerns and the evolution of electric propulsion technologies,” the report continued. “Electric boats, also referred to as e-boats or electrically powered vessels, replace traditional internal combustion engines with electric motors and batteries, delivering advantages in terms of efficiency, emissions reduction and operational cost savings.”

With that forecast in mind, Vision Marine’s unveiling of its newest e-boat offering, the Phantom, couldn’t have come at more opportune time. The company debuted the boat at the Miami International Boat Show 2024. The new vessel offers significant market advantages through its economic and environmental benefits. The company noted that the boat, which can comfortably seat up to 10 passengers, is engineered for efficiency. In addition, VMAR has the capacity to produce an estimated 300 units annually, with the potential to scale up to 1,500 units a year, at a cost that is 70% lower than that of fiberglass alternatives.

“We recognize a growing demand for rotomolded boats among our Florida clientele for several reasons,” said Roger Moore, the CEO of Nautical Ventures Marine Group, which has inked an exclusive distribution deal with VMAR. The Phantom’s affordability “enables entry-level ownership; they support both electric and gas motors, appealing to ecoconscious and traditional boaters alike; and their versatility makes the Phantom ideal for various activities, from fishing to leisure. With its 10-person capacity and maintenance-free design, the Phantom meets a wide range of needs.”

As Vision Marine gears up to meet industry demand for the new boat, the company’s new chief financial officer will bring invaluable expertise and insight. The company recently named Raffi Sossoyan as its new CFO, noting that the “strategic appointment marks a significant step as Vision Marine gears up for an ambitious phase focused on manufacturing, production, and delivery, underlining the company’s dedication to scaling its operations and enhancing its market footprint.”

Sossoyan has more than 25 years of experience in global financial and operational leadership. Most recently, he served as vice president of corporate treasury at Velan Inc., a Canadian multinational company. While there, Sossoyan managed financial operations amid global sales exceeding $370 million. Prior to that, as CFO at Valtech Fabrication Inc., he oversaw worldwide sales that totaled more than $50 million.

“Raffi’s robust experience in finance and operations within publicly listed companies, particularly his success at a TSX-listed entity, aligns perfectly with our strategic objectives as we escalate our manufacturing and delivery initiatives,” said CEO Alex Mongeon. “His leadership will be instrumental in fortifying Vision Marine’s financial strategies during this critical phase of our expansion.”

These two recent announcements underscore the Vision Marine Technologies commitment to leading the shift toward electric propulsion in the marine industry, fostering sustainability and achieving superior performance through its innovative E-Motion(TM) technology.

For more information, visit the company’s website at www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Correlate Energy, a publicly traded distributed energy solutions company, has positioned itself as the go-to company given the federal government’s push for greener buildings
• The government’s proposed definition of zero operating emissions buildings, seeks consistency with a framework for long-term goal-setting
• Correlate understands these changing tides and, through its three-pronged strategy, offers building owners and management the most technologically efficient and cost-effective ways to go green

Correlate Energy (OTCQB: CIPI), a publicly traded company positioned to capitalize on America’s move toward efficient energy sourcing and use, is aware of the growing pressure for buildings to become more energy efficient. This follows the federal government’s aggressive push for greener structures and its proposed definition geared toward increasing standardization, consistency, transparency, and accountability.

According to federal definitions, a zero operating emissions building is “Highly energy efficient, free of on-site emissions from energy use, and powered solely by clean energy sources.” The objective of this definition is to achieve consistency and lay down a framework for long-term goal setting. It leverages a building’s energy use as a foundation, offering incentives for existing building owners to improve their overall energy efficiency while providing a roadmap for new buildings to achieve energy efficiency upon construction (https://ibn.fm/aZIAW).

Correlate already recognizes that the energy grid in the U.S. is insufficient for the booming clean energy trend. In addition, it acknowledges that the current infrastructure poses a limit to green energy distribution. Still, it remains committed to helping buildings achieve net zero operating emissions, mainly by constructing the needed infrastructure to address this demand imbalance, while offering four main benefits with its offering. These include real cost savings, project investment funding, consistent long-term incentives, and robust customer demand.

Through its strategy of selling, retaining, and acquiring, Correlate has managed to carve out a significant market share. It is positioning itself as the all-in-one brand for total clean energy solutions, especially as the conversation around zero emissions buildings continues to proliferate and more stringent regulations are enforced.

This market positioning has seen various companies in the U.S. procure its products and services. Recently the company commissioned one of Illinois’ latest rooftop solar facilities for Continental Envelope’s manufacturing plant. This project is set to supply approximately 20-25% of the facility’s overall energy requirements (https://ibn.fm/mUav7). It has now also completed a solar project at American Tire Distributors headquarters in Huntersville, North Carolina. This project is expected to economically reduce CO2 emissions by 5,463 tons over the next two decades, helping the company reduce its carbon footprint (https://ibn.fm/jn0hz).

As the federal government continues its push for net zero emissions buildings, Correlate anticipates a growth in the demand for its products and services. In 2023, over $1.7 trillion was estimated to be invested in technologies such as solar and wind power, electric vehicles, and batteries, making it the most ever spent on clean energy in a single year. It is projected that 2024 might surpass that figure, and Correlate is positioning itself to ride the wave. With its tried and tested solutions, the company has already asserted itself as the go-to brand for decentralized energy generation.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• SenesTech, a rapidly growing company specializing in highly effective fertility control solutions for animal pests, recently announced multiple product distribution deals outside the U.S.
• In Europe, it entered into an agreement with Q-chem, a pest control product supplier in The Netherlands
• In Australia, SenesTech entered into an agreement with Evicom, an environmental management firm with distribution in the country, as well as in New Zealand and the surrounding region
• In Asia, the company partnered with Agro Technic PTE Ltd, a pest control product manufacturer and distributor headquartered in Singapore

SenesTech (NASDAQ: SNES), a rodent fertility control solutions provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce multiple distribution deals globally in what marks a huge milestone for the company, just two months into the new year. These deals bring YTD 2024 total revenue up more than 80% compared to YTD 2023 (https://ibn.fm/D9icH).

SenesTech also announced its foray into the European market with its distribution agreement with Q-chem, a pest control product supplier in the Netherlands. The move looks to tap into the growing demand for pest control products and services since the country first implemented an Integrated Pest Control (“IPM”) program four years ago with the explicit goal of reducing the reliance on anti-coagulant rodenticides. With its Evolve product, SenesTech is confident that it will dominate this market and become a leader in controlling rats with fertility control.

“Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” noted Mr. Fruendt (https://ibn.fm/6VwGH).

SenesTech is following the country’s requisite regulatory procedure with Q-chem’s help. The process is expected to progress quickly, after which the product will be introduced in Europe.

New Zealand and Australia have also been prime potential markets for SenesTech. Its distribution agreement with Evicom, an environmental management firm based in Australia with distribution throughout Australia, New Zealand, and the surrounding region, opens the company to these two lucrative markets.

“Evicom is thrilled to be appointed exclusive distributors of Evolve for Australia and New Zealand,” noted Simon de Bono, Evicom’s Managing Director.

“Knowing SenesTech really cares about humanely managing animal populations through innovative fertility control aligns with our business strategy,” he added (https://ibn.fm/0nLNe).

SenesTech also announced a distribution agreement with Agro Technic PTE Ltd, a Singapore pest control product manufacturer and distributor. This agreement will cover both a substantial initial stocking order and annual minimums. It will open SenesTech up to Singapore and surrounding regions, expanding its market reach and the potential number of customers it could acquire.

“Agro Technic has been at the forefront of bringing in innovative solutions for the public health sector since the 1970s. We continue to do so year on year, bringing to market solutions that are not only environmentally friendly but, most importantly, effective!” noted Heng Yiwei, Agro Technic’s Managing Director.

“The product range that SenesTech offers, is a perfect fit to our business model, long-term strategy, and market positioning and runs in tandem with the requirements of our garden city,” he added (https://ibn.fm/l2puL).

SenesTech’s management is optimistic that these distribution agreements, coupled with its superior, tried and tested Evolve product, will set the company up for even more success this year, even as it continues to explore new growth opportunities.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

Directors, managers, VPs, regulatory affairs personnel, and service providers of the logistics and operations verticals for the biopharma supply chain across Europe and North America are invited to attend the 3rd BioPharma Supply Chain & Logistics Nexus Conference being held April 25-26, 2024, at the Basel Mariott Hotel, Switzerland. The event aims to address critical issues and challenges in the supply chain and logistics within the biopharmaceutical industry.

The event is hosted by BioPharma Nexus, a premier company organizing prestigious conferences aiming to foster networking and business ties between pharmaceutical and biotech companies and their service providers. The focus lies in building robust relations such that the best healthcare services are available to patients worldwide. Service providers, managers, and company heads can identify and connect with partners to foster important scientific and healthcare collaborations.

Benefits of attending the conference:

• Establishing networking and business relations among powerful industry leaders.
• Gain insightful knowledge and learn about the latest trends in the biopharma spectrum.
• Connect with the industry leaders to stay updated with the latest technological advancements as well as the target audience.
• Learn the latest offerings and get innovative ideas and solutions for business operations.
• Showcase your product and business solutions on a unified conference platform.

The 3rd BioPharma Nexus Conference brings together global leaders and experts on the biopharma supply chain to provide invaluable insights. They will explore topics ranging from improving the supply chain transparency and sustainability in temperature-controlled logistics to novel technologies and trends in the pharmaceutical supply chain. Special attention will be given to the issues and opportunities faced by Contract Manufacturing Organizations (CMOs/CDMOs). New entities can leverage the nexus forum to gain visibility and network with key industry stalwarts.

To know more, please visit https://ibn.fm/nPR98

• CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
• Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
• The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
• The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
• Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer

With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://ibn.fm/huSZ8).

A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse commercial leadership roles in the U.S. and globally, spanning sales, marketing, and market access where she has been part of teams that commercialized and launched drugs in various therapeutic areas, from oncology and neurology to immunology.

In her current role as the Chief Commercial Officer of Roivant Sciences (NASDAQ: ROIV), a publicly traded biopharmaceutical company with a $9 billion market cap, Ms. Mahery is playing a vital role in facilitating Roivant’s transformation from a clinical development-focused company to an end-to-end biotech leader. She has worked to establish the company’s commercial operations and capabilities, efforts that have seen Roivant achieve profitable growth across its entire portfolio of over 10 affiliate companies called Vants. Ms. Mahery provides direct commercial leadership to the Vants during the start-up phase. Prior to taking up this role, she held multiple leadership roles at EMD Serono, Inc., a healthcare subsidiary of Merck KGaA.

“We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight, and vast pharma industry network will truly be invaluable,” conveyed Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy’s extensive experience and commercial leadership to assist in positioning the company for success.”

A strong supporter of innovation that brings value to patients, organizations, and society, Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (“GBM”) treatment, saying, “I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team.”

Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.

CNS Pharmaceuticals is currently undertaking a potentially pivotal study of Berubicin for the treatment of GBM. The company completed in January the planned enrollment of 247 participants across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland (https://ibn.fm/dPOwp). The company remains hopeful in its efforts to address GBM and intends to take advantage of the extensive expertise of Ms. Mahery and other members of its capable team to drive success.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Many Landlords across the United States currently face several obstacles in leasing commercial properties to cannabis-focused tenants, on the basis of ongoing federal restrictions that impact real estate factors such as insurance, financing, and permitting
• Zoned Properties has sought to bridge this supply gap, with a portfolio of investment properties seeking to address the needs of the regulated cannabis industry
• The company has recently announced plans to refocus its investment portfolio towards direct-to-consumer retail properties, simultaneously revealing their intentions to market one of their cultivation-oriented sites for sale
• Zoned Properties recently revealed that 3Q2023 revenues had risen by 17.2% YoY, whilst guiding for estimated full year rental revenues of $2.5 million over the course of 2024

In 2021, New York state officially legalized the usage of marijuana for recreational purposes; nevertheless, and nearly three years on from the landmark decision, cannabis supply for retail consumers remains painfully constrained. In April 2023, plans to build out a recreational cannabis dispensary in Harlem’s 125th street was thwarted by a lawsuit filed by a prominent Harlem business group, alleging that the planned dispensary would contribute to social issues in the neighborhood (https://ibn.fm/cB54T).

Despite cannabis being legal in 38 of 50 states for medical use and 24 states for recreational use, cannabis linked businesses are still faced with significant obstacles when looking to secure commercial properties for the cultivation or sale of marijuana-based products. With cannabis still illegal under federal law, commercial landlords seeking to rent out a mortgaged property face the risk of being called on a loan if a property is used for ‘illegal activity’; similarly, landlords open to leasing to cannabis tenants could face constraints in the form of city-specific zoning rules (https://ibn.fm/4XEBB). It is this unique conundrum which Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, is seeking to address.

The United States’ cannabis industry is expected to benefit from a remarkable 13.93% CAGR from 2024 to 2028, resulting in an annual market size of $67.15 billion by the end of 2028. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is seeking to capitalize on the industry’s burgeoning future by targeting commercial properties which have the potential to be acquired and rezoned or permitted for specific purposes, including the regulated and legalized cannabis industry. Separately and in addition to its core real estate development business, the company has sought to leverage upon their considerable commercial real estate expertise within their brokerage business in recent years; since 2021, Zoned Properties Brokerage has closed upwards of $80 million in commercial real estate deals nationally for clients.

Zoned Properties maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses. The company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company leases two properties which are operated as regulated cannabis cultivation and processing facilities. Nonetheless, the company has recently sought to refocus its investment portfolio towards direct-to-consumer properties located in states boasting both, a regulated and legal domestic cannabis industry and robust underlying cannabis consumer demand; in doing so, Zoned Properties has announced that it now considers its cultivation sites as legacy properties, reserving the optionality to potentially sell or leverage these holdings to unlock equity to be deployed towards its core business.

Considering its reaffirmed commercial priorities, Zoned Properties recently revealed that the company has listed its cultivation property located in Chino Hills, Arizona for sale at a purchase price of $16 million. A valuable yet non-core asset within the company’s portfolio, the sale of the Chino Valley property could help further streamline Zoned Properties’ portfolio and help recalibrate its real estate offering towards more direct-to-consumer focused properties (https://ibn.fm/WWgDm).

“As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy, represents a significant capital reallocation opportunity for Zoned Properties. We expect that, if and when the Chino Valley Property is sold, the non-dilutive proceeds from the sale would be instrumental in supporting the company’s future real estate portfolio acquisition plans,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

• Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study
• John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension
• With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive
• This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows the company’s Investigational New Drug (“IND”) application earlier in the year.

The HYPER-H23-1 clinical trial, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” will seek to explore the overall effectiveness of its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension. The primary objective will be to evaluate the safety and tolerability in hypertensive patients, with secondary objectives including efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing (https://ibn.fm/ch6DA).

According to John Docherty, President of Lexaria, this clearance by the FDA demonstrates its technology’s overall potential, having met the FDA’s high level of regulatory scrutiny.

“This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization,” noted Mr. Docherty.

Since 2018, Lexaria has conducted five human clinical studies for its DehydraTECH-CBD on 134 healthy, normal, and hypertensive volunteers. The results have been overwhelmingly positive, evidencing reductions in resting blood pressure over both acute and multi-week dosing regimens. The studies also produced zero serious adverse events, pointing to DehydraTECH’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

With HYPER-H23-1, Lexaria looks to build on the success of its previous studies, ultimately asserting the superiority of its technology, while also inching closer to tapping into the hypertension treatment market, which was valued at $31.76 billion in 2022, and is expected to reach $43.18 billion by 2030 (https://ibn.fm/Uror5).

“We look forward to commencing this important clinical trial and building upon the wealth of early-stage clinical data we have gathered and presented to the FDA to date demonstrating the safety, efficacy, and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients,” noted Mr. Docherty.

This is a huge milestone for Lexaria and its team, especially following the plans to commence with its diabetes and weight loss animal study, coupled with doubling down on its GLP-1 clinical studies for the 2024 calendar year. All these steps reflect the company’s commitment to creating shareholder value and further developing its DehydraTECH technology, which has the potential to be a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The Canadian Shield hosts numerous nickel, copper, gold, and platinum group metals
• Fathom targets high-grade nickel sulfide discoveries for use in EV and green energy markets
• Fathom operates the Albert Lake Project and the Gochager Lake Project, both located in Saskatchewan’s Trans Hudson Corridor
• Favorable results revealed from recent drilling at the Albert Lake Project
• Company recently closed the second and final tranche of its non-brokered offering, total gross proceeds totaled $4,571,063 when combined with the first tranche

The Canadian Shield’s rich mineral endowment presents abundant mining exploration and drilling opportunities. Covering a significant portion of Canada, this vast geological region hosts numerous nickel, copper, gold, and platinum group metals – both known and waiting to be discovered.

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is an energy metals exploration company targeting high-grade nickel sulfide discoveries for use in the rapidly expanding electric vehicle and green energy markets. Headquartered in Calgary, Alberta, FNICF operates the Albert Lake Project and the Gochager Lake Project, both located in Saskatchewan’s Trans Hudson Corridor.

The company commenced drilling at its fully permitted Albert Lake Project in early February 2024 and anticipates moving to its Gochager Lake Project in March.  There is a wide variety of data-driven and drill-ready targets at each project that will be drilled. Some targets are brand new while others are returning to previous targets with new knowledge on how to approach them. Time domain electromagnetic (“TDEM”), Borehole electromagnetic (“BHEM”) geophysical data, geochemical anomalies, as well as knowledge about subsurface structural controls have all gone into developing the drill targets for this year and Fathom is excited for the potential of what may be unearthed.

The Rottenstone Mine produced high-grade nickel, copper, and platinum group elements (“PGE”) from 1965 to 1969. Output at the mine reached impressive levels at 3.28% for nickel, 1.83% for copper, and PGE at 9.63 grams per ton, highlighting the area’s rich mineralization and potential for further development.

Albert Lake is a nickel sulfide deposit – a strategic focus for Fathom. Unlike limonite ore and saprolite ore, class 1 nickel sulfide is a preferred component in EV batteries, stainless steel, aerospace components, chemical processing equipment, electrical resistance wires, and turbine engines.

Investor interest appears bullish on Fathom’s prospects. The company recently announced that it closed the second and final tranche of its non-brokered offering, comprised of flow-through and non-flow-though (“NFT”) units. Total gross proceeds from the offering totaled $4,571,063 when combined with the first tranche that closed on December 22, 2023 (https://ibn.fm/SXOvo). The company intends to use the net proceeds from the NFT Units for exploration, development, working capital, and general corporate purposes.

Fathom’s seasoned management team leverages extensive experience in the mining and exploration sectors. CEO, VP of Exploration, and Co-Founder Ian Fraser brings over 35 years of expertise with notable contributions to the development of significant gold mines such as Casa Berardi, Komis, and Cisneros. Doug Porter serves as President, CFO, and Director at Fathom, bringing extensive financial and managerial experience from roles held at prominent resource companies like Elan Coal Limited, Altitude Resources Limited, and StimWrx Oilfield Services Limited.

For more information, visit the company’s website at www.FathomNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to FNICF are available in the company’s newsroom at https://ibn.fm/FNICF

• EU raised 2030 binding renewable energy target to a minimum of 42.5%, aims to become climate-neutral by 2050
• U.S. set goal of 100% clean energy by 2035
• TURB aligned with renewable energy shift with Sunbox Home and Sunbox Industry
• TURB’s all-in-one systems leverage AI to improve efficiency, prevent price shocks, and maximize cost savings
• Turbo Community allows members with large PV installations to gain ownership of production, store extra power, and sell energy to market

The European Union recently raised its 2030 binding renewable target to a minimum of 42.5% with the aim of reaching 45% and becoming a climate-neutral continent by 2050 (https://ibn.fm/djHTQ). Across the Atlantic, the United States has set an even more ambitious goal of 100% clean energy by 2035 (https://ibn.fm/cqFtw).

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on the growing trend with its comprehensive range of patented energy storage and management solutions. By aligning its products and services with the evolving regulatory landscape, TURB aims to meet the growing needs of residential and commercial consumers while advancing the green transition.

TURB’s Sunbox Home is an AI-powered all-in-one energy storage system that manages consumption at each point on a home’s energy grid to maximize efficiency and cost savings (https://ibn.fm/Dh3X6). The battery optimizes energy management by strategically releasing stored energy during peak benefit periods while drawing back from the grid when electricity costs are low, ensuring efficient fulfillment. The system integrates electric vehicle charging capabilities with versatile modes, allowing consumers to charge at maximum speed, cost savings, or sustainably harnessing energy solely from the sun.

Sunbox’s protection modes safeguard consumers against price shocks through four customizable management modes. The Smart Mode leverages AI to strike a perfect balance between power consumption and savings on electricity bills. The system’s BackUp Mode allows users to designate a portion of the battery for blackout protection, ensuring system reliability. In Peak Shaving mode, users can reduce power bill costs by specifying which part of the storage delivers energy during overconsumption periods. Lastly, Sunbox’s Storm Protect mode activates an intelligent protection system that fully charges batteries in anticipation of upcoming storms based on weather forecast data.

TURB’s Sunbox Industry provides reliable energy generation and management for commercial businesses (https://ibn.fm/cG4eA). The system connects directly to rooftop panels and can be expanded with TURB’s Retrofit feature to leverage solar surpluses. With management modes like Sunbox Home, Sunbox Industry enables businesses to maximize power during outages, ensuring system efficiency and round-the-clock reliability.

Turbo Energy goes beyond pioneering innovative energy systems that align with the global shift towards renewable energy. The company additionally empowers its clients to become part of the energy revolution through its Turbo Community (https://ibn.fm/8GxXV).

The Turbo Community enables users with large photovoltaic installations to gain ownership of their energy production by storing extra power for later use or selling it to the market as producers. Additionally, Turbo Energy provides opportunities to rent or finance solar energy systems, enabling users to access clean energy without significant upfront investment, maintenance issues, or installation concerns.

From its innovative products and services to its growing client network, Turbo Energy is dedicated to advancing the green transition. Led by a team with decades of technological, financial, and sales experience, the company is committed to a cleaner future amid the global push for renewable energy resources.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Freight Technologies recently announced a significant collaboration with Envases Universales, one of the world’s largest packaging companies
• The collaboration, anchored in a contract estimated to be valued at over $5 million, is intended to help manage Envases’ transportation needs over the next year
• According to Fr8Tech, the contract demonstrates Fr8App’s commitment to delivering exceptional transportation services as well as its ability to meet the evolving needs of its clients
• The collaboration with Envases Universales follows a Jan. 2024 contract with Kawasaki Motores de Mexico for cross-border logistics services

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company, recently announced that its custom-developed, industry-leading Fr8App freight matching platform has been selected by Envases Universales, one of the world’s largest packaging companies, to help manage Envases’ transportation needs over the next 12 months. According to the company, Fr8App was awarded 24 dedicated routes, mostly from Mexico to the U.S., through Envases’ annual 2024 request for quotation (“RFQ”) (https://ibn.fm/0E0rw).

Powered by artificial intelligence (“AI”), machine learning, and cloud computing, the F8App freight-matching platform offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region. It seamlessly connects shippers with an extensive network of carriers and drivers, ensuring reliable and efficient transportation of cargo and optimizing logistics. Moreover, Fr8App uses innovative technology and solutions like live pricing, real-time tracking, fleet management, transportation management, digital freight marketplace, broker, and committed capacity planning to improve matching and operation efficiency.

According to the Feb. 26 news release announcing the significant collaboration with Envases, the awards, estimated to be worth more than $5 million, demonstrate Fr8App’s commitment to delivering exceptional transportation services as well as its ability to meet the ever-changing needs of its clients. Moreover, they underline Fr8App’s expansive network and ability to manage cross-border logistics efficiently. Over the next year, Fr8App will oversee the transportation of over 1,600 loads, ensuring that Envases Universales’ goods are delivered securely and in a timely fashion.

“We are thrilled to have been chosen by Envases Universales to help manage their transportation needs over the coming year,” conveyed Fr8App’s CEO Javier Selgas. “This collaboration not only speaks to our capabilities but also to the trust Envases Universales has in our ability to deliver exceptional service. It also highlights the importance of tactical collaboration between the companies in driving profitable growth and achieving excellence in dependable and efficient logistics execution.”

Fr8Tech nevertheless pointed out that the value of the awarded routes may change based on the needs of Envases Universales, as influenced by the customer demand, or the production output. The company, however, believes the likelihood of Envases Universales experiencing lower-than-expected customer demand or production levels – which may lead to adjustments to the number of awarded routes – is low. Fr8Tech bases this low-probability outcome on Envases Universales’ market leadership in the packaging industry.

Envases Universales is a leading global supplier of quality packaging solutions. The company specializes in the manufacture and supply of aluminum beverage packaging, PET packaging, and food and industrial packaging. It is comprised of 84 manufacturing facilities across the world (https://ibn.fm/VjXOc).

The collaboration with Envases Universales follows the materialization of a contract that Fr8Tech entered with Kawasaki Motores de Mexico, a division of Kawasaki Heavy Industries, Ltd., for cross-border logistics services. Announced Jan. 16, the contract will see Fr8App orchestrate the cross-border logistics for Kawasaki’s iconic Jet Ski models (https://ibn.fm/prruE).

“At Freight Technologies, we take immense pride not only in what we do but also in being chosen by global industries to revolutionize cross-border logistics. This contract with Kawasaki Motores de Mexico is a testament to our commitment to delivering cutting-edge solutions to a variety of industries,” said Selgas of the collaboration.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications IBN (InvestorBrandNetwork) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com